...
首页> 外文期刊>Journal of Cancer Research and Clinical Oncology >Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment
【24h】

Shorter disease-specific survival of ER-positive breast cancer patients with high cytoplasmic Src kinase expression after tamoxifen treatment

机译:他莫昔芬治疗后具有高细胞质Src激酶表达的ER阳性乳腺癌患者的疾病特异性生存期缩短

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Src kinase, a non-receptor tyrosine kinase, is overexpressed and highly activated in a number of human cancers and appears to show a significant relationship with breast cancer progression. Recent in vitro studies have suggested that Src kinase may be involved in tamoxifen resistance.
机译:Src激酶是一种非受体酪氨酸激酶,在许多人类癌症中均过表达并高度活化,似乎与乳腺癌的进展密切相关。最近的体外研究表明,Src激酶可能与他莫昔芬耐药有关。

著录项

  • 来源
    《Journal of Cancer Research and Clinical Oncology》 |2012年第2期|p.327-332|共6页
  • 作者单位

    Institute of Cancer, College of Medical, Veterinary and Life Sciences, University of Glasgow, Western Infirmary, McGregor Building, Dumbarton Road, Glasgow, G11 6NT, UK;

    Institute of Cancer, College of Medical, Veterinary and Life Sciences, University of Glasgow, Western Infirmary, McGregor Building, Dumbarton Road, Glasgow, G11 6NT, UK;

    Department of Surgery, Crosshouse Hospital, Kilmarnock Road, Kilmarnock, KA2 0BE, UK;

    Institute of Cancer, College of Medical, Veterinary and Life Sciences, University of Glasgow, Western Infirmary, McGregor Building, Dumbarton Road, Glasgow, G11 6NT, UK;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

    Src kinase; ER-positive breast cancer; Disease-specific survival; Immunohistochemistry; Tamoxifen;

    机译:Src激酶;ER阳性乳腺癌;疾病特异性存活;免疫组织化学;他莫昔芬;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号